Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (311-320 of 466) with videos related to

Pageof 47
Sort By:
Blood|December 1, 2005
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational statusMia Thorsélius, Alexander Kröber, Fiona Murray, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
Hemasphere|June 24, 2022
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic LeukemiaNadine Kutsch, Christian Pallasch, Thomas Decker, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Wolfram Klapper, Olivier Hermine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.
Pageof 47

Showing results (311-320 of 466) with videos related to

Sort By:
Pageof 47
Blood|December 1, 2005
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational statusMia Thorsélius, Alexander Kröber, Fiona Murray, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
Hemasphere|June 24, 2022
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic LeukemiaNadine Kutsch, Christian Pallasch, Thomas Decker, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Wolfram Klapper, Olivier Hermine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.
Pageof 47